Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 9, 2013

Evotec, Dow AgroSciences Team Up in Chemical Proteomics Effort

  • Evotec and Dow AgroSciences are collaborating in an effort to support compounds in development at the latter firm.

    Under the terms of the research agreement, Dow will leverage Evotec’s chemical proteomics services. Evotec will be performing quantitative chemical proteomics services to clear up Dow’s phenotypic screening results. Financial terms were not disclosed.

    “We look forward to working with Dow AgroSciences on this project,” Evotec COO Mario Polywka, Ph.D., said in a statement. “This collaboration highlights the broad applicability of Evotec's industry leading chemical proteomics platform to determine cellular target affinities and mechanisms of action on a proteome wide level and in a native context.”

    Added Dow’s William Kleschick, Ph.D., discovery global leader: “This collaboration enhances [our] technology toolbox to accelerate our efforts to deliver novel solutions to our customers around the world.”

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »